A series of experiments was performed to deter mine the role of interleukin (IL)-l in the induction of tolerance to global ischemia in Mongolian gerbils, In Group I, a 2-min "preconditioning" ischemia protected CAl hippocampal neu rons in gerbils subjected to 3,5 min ischemia 3 days later. CA J neuronal density was: sham, 17 1 ± 3/mm; 3,5 min ischemia, 30 ± 30/mm; 2 and 3.5 min ischemia 162 ± 6/mm, Experiments in Group II addressed the role of IL-l in the induction of tolerance by sublethal ischemia, Arterial IL-l ex and IL-l f3 became el evated between 1 and 3 days after a 2-min ischemic exposure. IL-lex was: sham, 6.4 ± 0.6 ng/ml; and 2-day, 10.2 ± 1.2 ng/m!. IL-lf3 was: sham, 6.4 ± 0.5 ng/ml; and 2-day, 17.3 ± 2 ng/m!. Recombinant human IL-l receptor antagonist (IL-l ra) i.p. blocked ischemic tolerance induction by 2-min preconditioning ischemia: 2-min ischemia + vehicle, 162 ± 6/mm; and 2-min
Current efforts to develop effective stroke therapy are generally directed at arresting progressive brain damage in the ischemic penumbra (Ginsberg and Pulsinelli, 1994; Hossmann, 1994) . Although a variety of experi mental therapies aimed at counteracting one mediator or another demonstrate significant neuroprotection in ani mal models, they tend to perform weakly, if at all, in clinical trials of acute stroke in humans. One possible explanation for the difficulties encountered in efforts to develop an effective stroke treatment is that the conven tional search for a single or dominant mediator of pro gressive ischemic brain damage is incompatible with the essential nature of the problem. The multiplicity of fac tors that participate in progressive ischemic brain injury and their intricate interconnections, in the aggregate, can ischemia + IL-I ra, 67 ± 17/mm. Experiments in Group III assessed the capacity of IL-l to induce tolerance to brain isch emia. IL-l ex i.p. (0, 10, 20 j-Lg/kg) for 3 days prior to 3.5-min forebrain ischemia provided significant CA 1 neuroprotection in a dose-dependent manner: 2 ± 2, 68 ± 83, and 129 ± 42/mm, respectively. IL-l f3 (15 j-Lg/kg) in combination with either IL Ira (100 mg/kg) or IL-J ra vehicle i.p. on the same schedule demonstrated a significant CAl neuroprotection that could be nullified by IL-I ra: IL-l f3 + IL-I ra vehicle, 153 ± 16/mm; and IL-If3 + IL-lra, 67 ± 36/mm. Recognition that tolerance arises from stimulation of a known receptor (IL-IRI) permits molecu lar analysis of the intracell ular signaling that is critical for production of that state. Key Words: Mongolian gerbil Ischemic tolerance-Interleukin-l .
produce dramatic tissue damage. Each factor by itself, however, may have only minor pathophysiologic impor tance (Hallenbeck and Dutka, 1990; Hallenbeck and Fre richs, 1993) .
It is very difficult to deduce, by analyzing the inter relationships among the various causal factors, an effec tive intervention for a problem that stems from a con stellation of minor causes. The need for such a deductive approach may be circumvented by studying states in which animals become tolerant to brain ischemia (Fre richs et aI., 1994) . Identification of the adjustments made by animals during natural or induced states of tolerance could guide investigators toward an understanding of ef fective therapeutic principles that would be difficult to discern through an analysis of mediator cascades. The goal would be to identify the intracellular signalling step(s) that can globally modulate the mediator network that causes progressive ischemic brain damage. In a sense, animals under these circumstances may be able to teach investigators how to solve this complicated problem.
Brief durations of "preconditioning" ischemia and hyperthermia have been observed to induce remarkable tolerance against subsequent, more severe ischemia that would otherwise lead to cell death in hippocampal CA 1 neurons (Kitagawa et aI., 1990; Kirino et aI., 199 1; Kitagawa et aI., 1991b) . However, no previous reports have clearly defined what is responsible for the initiation and development of such tolerance. If a ligand-receptor interaction could be identified that induced tolerance, it would greatly facilitate characterization of the intracel lular signaling pathways that regulate the tolerant state.
Interleukin (IL )-1 is a key immunomodulator that acts rapidly and mediates a wide range of immune and in t1ammatory responses as well as the acute phase reaction (Oppenheim et aI., 1986) . It is specifically antagonized by a recombinant human IL-l receptor antagonist (IL Ira), M.W. 18 kDa that has no apparent agonist function (Lennard, 1995) . Stresses such as brain ischemia and surgical brain trauma have been shown to induce marked expression of IL-l in neurons and microglia (Minami et aI., 1992; Liu et aI., 1993; Tchelingerian et aI., 1993) . Although neurons possess IL-l receptors in the hippo campus (Ban et aI., 199 1), receptor-mediated effects of this cytokine in the brain are just beginning to be studied. Inhibition of IL-l activity and receptor binding have been shown to attenuate ischemic and excitotoxic neu ronal damage and edema formation (Relton and Rothwell, 1992; Martin et aI., 1994; Garcia et a!., 1995; Yamasaki et aI., 1995) . The present work is based on the hypothesis that exposure to IL-l induces resistance to ischemia, which would otherwise lead to neuronal cell death, in the gerbil hippocampus.
METHODS
Mongolian gerbils (Meriones unguiculatus), 13�15 weeks of age, were subjected to the 18 experiments that make up this study. The experiments cluster into three groups. Experiments in Group I (Table 1) demonstrate the ability of a precondition ing exposure to sublethal ischemia to induce tolerance to a subsequent neuron-damaging ischemia (n = 20). Experiments in Group II (Table 2) address the role of IL-I in the induction of tolerance by sublethal ischemia (n = 64). Experiments in Group III (Table 3 ) assess the capacity of IL-I to induce tol erance to brain ischemia (n = 55). All experimental procedures in the present work were reviewed and approved by the Na tional Institutes of Health Animal Care and Use Committee.
Animals were anesthetized with 1.5% halothane in 30% 0i 70% N20 (vol/vol). Both common carotids were exposed through a midcervical incision and gently separated from their carotid sheaths. In sham-operated animals, both common ca rotids were exposed but not occluded. In experimental animals, both common carotids were simultaneously occluded with min iature vascular aneurysmal clips for either 2 or 3.5 min to produce transient global ischemia of the forebrain. Body tem perature was monitored with rectal and temporal muscle ther mometers and temporal muscle temperature was regulated at 37.2 ± 0.1 °C by a feedback-controlled heating lamp and pad during surgery. After removal of the vascular clips, restoration of blood flow was verified by direct observation through a microscope. Rectal temperature was monitored following clip removal during the first 2 h of reperfusion. Surgical incisions were sutured and disinfected; animals were allowed free access to food and water, and were housed at constant temperature (23°C) under diurnal light conditions. To produce ischemic tolerance, gerbils were initially exposed to "preconditioning" ischemia for 2 min and were then subjected to a second, po tentially neuron-damaging ischemia for 3.5 min 3 days later. These experiments are depicted in Table I .
In order to determine whether 2 min of preconditioning isch emia increased circulating IL-I in the blood, serum contents of IL-Ia and IL-l(3 were measured by competitive enzyme im munoassay (Cytokit Red mla and ml(3, respectively) (Cyto Immune Sciences, College Park, MD, U.s.A.). The anti-murine antibodies in these assays are known to cross react with rabbit and rat IL-I, and the sensitivity of the assay is 0.19 ng/m!. Blood (200 [LI) was withdrawn from the common carotid artery (under pent9barbital anesthesia, 40 mg/kg, i.p.) from control and experimental animals at 3 h, 1,2, and 3 days after 2-min of ischemia or sham operation. Recombinant human IL-I receptor antagonist (IL-Ira), kindly donated by Amgen (Boulder, CO, U.S.A.), was dissolved in 10 mM sodium citrate buffer, pH 6.8, with 150 mM N aCI, 0.5 mM EDT A, and 0.1 % Tween 80. Following sham operation or 2 min of ischemia, gerbils re ceived a daily i.p. injection of either IL-l ra (100 mg/kg) or the IL-J ra vehicle in a volume of 0.5 ml/kg at 0 (30 min after the procedure), 1 or 2 days before undergoing 3.5 min of ischemia on day 3. Surviving hippocampal CAl neurons were counted on day 10. These experiments are depicted in Table 2 .
Recombinant murine IL-I a, 2.4 x 106 U/fLg (Sigma Chemi cal, St. Louis, MO, U.S.A.) was dissolved in 10 mM phosphate buffered saline (PBS), pH 7.4, with 0.1 % bovine serum albu min (endotoxin free). Recombinant human IL-I(3, 1.9 x 104 U/[Lg containing 2.5 endotoxin units/mg protein (a gift from Dr. Craig W. Reynolds, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, MD, U.S.A.) was dissolved in 10 mM PBS, pH 7.4. The capacity of IL-l to induce tolerance to ischemia was investigated by ad ministering IL-I a (10 or 20 [Lg/kg) or its vehicle i. p. in a volume of 0.5 ml/kg on days 0, I, and 2 before subjecting gerbils to 3.5 min of ischemia on day 3 and counting intact CA 1 
RESULTS
There was no significant difference in postischemic temperatures among the animals in the present study. Specifically, during the first several hours after injection of IL-lex, IL-l(3, or vehicle, average body temperature rose only slightly, O.I-OAoC, with no difference between groups. After 3.5 min of ischemia, temperature rose 1.2-1.6°C, with no difference between the same groups. None of the gerbils showed epileptic motor activity. In sham-operated animals, no neuronal damage was evident in the CA I region of the hippocampus 7 days after the procedure (CA I neuronal density, 171 ± 3/mm). Tran sient ischemia for 2 min also caused no detectable dam age (167 ± 3/mm), but 3.5-min of ischemia caused ex tensive neuronal destruction in the hippocampal CAl sector measured 7 days later (30 ± 30/mm). In most animals subjected to preconditioning ischemia for 2 min followed by 3.5 min of ischemia 3 days later, CA 1 neu rons were spared (162 ± 6/mm) (Fig. I) .
The stress of surgery led to a small but significant elevation of circulating IL-l ex and IL-I(3 that was sus tained between 3 h and 3 days after the procedure, com pared with controls. Serum contents of both IL-Iex and IL-l(3 were significantly increased 1-3 days after expo sure to 2 min of ischemia as compared to control animals and sham-operated animals (IL-I ex: control, 4 ± 0.1 ng/ ml; sham, 6A ± 0.6 ng/ml; and 2 days, J 0.2 ± 1.2 ng/ml. IL-I(3: control, 3 ± 0.7 ng/ml; sham, 6A ± 0.5 ng/ml; and 2 days, 17.3 ± 2 ng/ml) (Fig. 2) .
Gerbils were subjected either to a sham operation or a 2 min preconditioning ischemia followed by daily injec tions of vehicle or IL-J ra that started 30 min after the procedure. After 3 days, animals underwent 3.5 min of potentially neuron-damaging ischemia (Fig. 3) . Sham operation followed by three daily injections of vehicle (sham + vehicle) offered no CA 1 neuroprotection during the subsequent 3.5 min period of ischemia (22 ± 23/mm). A sham operation plus IL-l ra (l00 mglkg) injected 30 min later (day 0), and I and 2 days before 3.5 min of ischemia on day 3 (sham + IL-I ra) showed a trend to ward neuroprotection that did not reach statistical sig nificance (49 ± 32/mm). Preconditioning ischemia fol lowed by daily vehicle injections provided clear-cut CAl neuroprotection during a subsequent 3.5-min period of ischemia (2 min + vehicle: 162 ± 6/mm). IL-lra, injected 30 min (day 0), and 1 and 2 days after a 2-min period of preconditioning ischemia, inhibited the expected neuro nal protection in animals subjected to a subsequent 3.5 min of ischemia (2 min + IL-lra: 67 ± l7/mm). Daily injection of IL-l a over a 3-day period protected CAl hippocampal neurons from 3.5 min of global isch- emia in a dose-dependent manner as compared with IL Ia vehicle injections. Neuronal counts were 2 ± 2/mm for vehicle, 68 ± 83/mm for IL-la (10 J.1g/kg), and 129 ± 42/mm for IL-la (20 J.1g/kg). No CAl neuronal death was noted in five of the ' eight animals treated with IL-la (20 J.1g/kg) · (Fig. 4) . IL-ll3 was also observed to induce ischemic tolerance, as demonstrated in Fig. 5 . A combined daily injection of the vehicles for IL-113 and IL-I ra on each of 3 days prior to 3.5 min of ischemia did not reduce the loss of CAl neurons after ischemic exposure (vehicle + vehicle: 23 ± 22/mm). IL-ll3 combined with the vehicle of IL-Ira on the same daily injection schedule provided marked pro tection with greater than 90% of CAl neurons surviving 3.5 minutes of ischemia (IL-ll3-vehicle: 153 ± 16/mm). IL-lra) injected daily for 3 days prior to 3.5 min of isch emia was associated with a slightly higher average count of surviving CAl neurons than the combined vehicle injection (49 ± 32/mm), but this difference did not reach statistical significance. The protection afforded by IL-l f) plus IL-Ira vehicle was greatly reduced when IL-1 f) was co-injected with IL-lra (IL-1f) -IL-Ira: 67 ± 36/mm).
DISCUSSION
In this study, serum levels of both IL-1 a and IL-1 f) increased between 1 and 3 days after subleth a l ischemia produced by 2 min of bilateral common carotid artery occlusion in gerbils. This sublethal ischemia protected CAl neurons from an otherwise lethal ischemia of 3.5 min 3 days later. Administration of IL-J ra blocked in duction of ischemic tolerance in animals subjected to such sublethal ischemia. Both IL-1 a and IL-1 f) were found to substitute for the sublethal ischemia with re spect to induction of ischemic tolerance, and this effect was blocked by IL-1ra. Results demonstrate that IL-l is necessary for induction of tolerance to neuron-damaging ischemia by prior exposure to sublethal ischemia (pre conditioning) and that IL-1 is sufficient to directly and specifically induce tolerance to 3.5 min of global fore brain ischemia in the gerbil via a ligand-receptor inter action. Since the dosages of IL-1 used in this study did not provide total CA 1 protection, we cannot distinguish (without an extensive dose-response design to optimize the IL-l effect) between the possibility that IL-1 is the only stimulus required for the development of full isch emic tolerance and the possibility that IL-1 is a major factor, acting in concert with other factors. Incomplete suppression by IL-1ra of ischemic tolerance produced by preconditioning ischemia or IL-1 is attributed to the ca pacity of IL-1ra to attenuate direct IL-1-mediated isch emic damage as an independent effect (Relton and Rothwell, 1992; Martin et aI., 1994; Garcia et aI., 1995; Yamasaki et aI. , 1995) .
IL-1 administration 1-3 days prior to injury has been shown to protect hearts from ischemia/reperfusion injury and to reduce hyperoxic lung damage (White et aI., 1987; Brown et aI., 1990; Maulik et aI., 1993) . Several reported effects of IL-l could contribute to its capacity to produce a state of ischemic tolerance in animals: IL-l induces acute down-regulation of IL-IRI mRNA in perivascular cells (Ericsson et a!., 1995) ; stimulates production of IL-lra and tumor necrosis factor binding protein, which can inhibit the release and activity of IL-1 and TNF-a, respectively (Bargetzi et aI., 1993; Marsh et aI., 1994) ; and can also increase production of manganese superox ide dismutase, which could counteract damage in brain due to reactive oxygen species (Masuda et aI., 1988) . Other possible protective mechanisms involve release of antiinflammatory and anticoagulant cyto ki nes suc h as transforming growth factor-f), IL-I0, IL-4 (Jungi et aI. , 1994; Frankenberger et aI., 1995) and inhibition of ap optosis by Bcl-2 effects on IL-lf)-converting enzyme (ICE) (Chen et aI., 1995) . IL-1 is induced in brain by ischemia (Minami et aI., 1992; Liu et aI., 1993) and systemically by hyperthermia (Blake et aI. , 1994) . Elabo ration of this "alarm hormone" (Sch6bitz et aI., 1994) could be a generic mechanism for tolerance induction by stressful stimuli.
This work does not identify the cells directly affected by IL-1 binding to their receptors nor the consequent intracellular signaling that confers the ischemic brain tol erance. Circulating leukocytes, endothelium, and events at the blood-endothelial interface are strongly influenced by cytokines (reviewed in Hallenbeck, 1996) . In addi tion, tolerance to lipopolysaccharide (LPS), a state me diated by cytokines, involves macrophages (Freudenberg and Galanos, 1988) . These considerations raise the pos sibility that the observed tolerance arises from mecha nisms that act systemically. Although penetration of the blood-brain barrier by IL-l is, in .general, low (Sch6bitz et aI., 1994) , systemic IL-l may recruit IL-l expression in brain, as has been observed after systemic LPS ad ministration (Gabellec et aI. , 1995) particularly in the region of the circumventricular organs (Breder et aI., 1994) . Systemic IL-l may also signal brain cells indi rectly by cytokine-receptor interaction in the vasculature and other blood-brain-barrier-related sites (Ericsson et aI., 1995) . Systemic administration of IL-1 can alter CBF and disrupt the blood-brain barrier (reviewed in SchObitz et aI., 1994) . These considerations suggest that the ob served tolerance could also arise from mechanisms that act within the brain.
The steps that culminate in the development of toler ance in this experimental paradigm proceed from an identifiable initiation point in contrast, for example, to experiments in which tolerance is induced by a bout of sublethal ischemia. The signaling receptor for IL-I is the 80 kDa glycoprotein, IL-\ RI. The other IL-\ receptor, a 68 kDa IL-IRU, has a very short intracytoplasmic do main comprised of 29 amino acids (in contrast to 215 amino acids of fL-\ RI) and does not appear to transmit intracellular signals so that it functions instead as a "de coy" or inhibitor of IL-I (Brooks and Mizel, 1994; Sak latvala, 1995) . The several modes of signal transduction from IL-l RI include the sphingomyelinase cycle, with its production of ceramide; protein kinases, e. g. , p54 MAP kinase, 13-casein kinase, hsp 27 kinase; phosphatases; and such transcription factors as API and NFKB (O'Neill, 1995) . Identification of the critical steps for tolerance induction that proceed from this initiation point may permit a molecular basis for the regulation of tol erance to be determined.
